Lobbying Information
Subject Matters
- Aboriginal Affairs
- Agriculture
- Arts and Culture
- Broadcasting
- Constitutional Issues
- Consumer Issues
- Defence
- Education
- Employment and Training
- Energy
- Environment
- Financial Institutions
- Fisheries
- Forestry
- Government Procurement
- Health
- Immigration
- Industry
- Infrastructure
- Intellectual Property
- Internal Trade
- International Relations
- International Trade
- Justice and Law Enforcement
- Labour
- Mining
- Regional Development
- Science and Technology
- Small Business
- Sports
- Taxation and Finance
- Telecommunications
- Tourism
- Transportation
Subject Matter Details
Legislative Proposal, Bill or Resolution
- Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry
- Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products
- Income Tax Act as it relates to biopharmaceutical products
- Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
Legislative Proposal, Bill or Resolution, Regulation
- Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
- Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
Policies or Program
- Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Acess to Medicines, and TRIPs "flexibility"
- Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs
- Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
- Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
- Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
- Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
- Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union
- Health Canada's Progressive licensing framework as it relates to the review and approval of biopharmaceutical products
- National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework
- Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB)
- Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
- Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
- The government's Science and Technology strategy as it relates to the biopharmaceutical industry
- World Health Organization issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG)
Regulation
- Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
- New Substances Notification Regulations as it relates to the biopharmaceutical industry
- Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
- Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
- Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
- Smart Regulations as it relates to the biopharmaceutical industry
Communication Techniques
-
Written communication
-
Oral communication
-
Grass-roots communication
Government Institutions
-
Agriculture and Agri-Food Canada (AAFC)
-
Canadian Institutes of Health Research (CIHR)
-
Canadian International Development Agency (CIDA)
-
Canadian International Trade Tribunal (CITT)
-
Competition Tribunal (CT)
-
Environment Canada
-
Finance Canada (FIN)
-
Foreign Affairs and International Trade Canada (DFAITC)
-
Health Canada (HC)
-
Industry Canada
-
Justice Canada (JC)
-
Members of the House of Commons
-
National Research Council (NRC)
-
Natural Sciences and Engineering Research Council (NSERC)
-
Office of the Information and Privacy Commissioner (OIPC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Public Works and Government Services Canada
-
Revenue Canada (RC)
-
Senate of Canada
-
Solicitor General Canada (SGC)
-
Statistics Canada (StatCan)
-
Treasury Board Of Canada Secretariat (TBS)
-
Veterans Affairs Canada (VAC)
Government institutions added through a monthly communication report
- Fisheries and Oceans Canada (DFO)
- Natural Resources Canada (NRCan)
In-house Organization Details
Description of the organization's activities
Canada's Research-Based Pharmaceutical Companies (Rx&D) is the industry association of Canada's research-based pharmaceutical industry. The companies that make up the membership of Rx&D are engaged in the research and development, production, marketing, and servicing of prescription and non-prescription pharmaceutical products. Rx&D members employ more than 22,000 people across Canada. Comprised of companies of all sizes, Rx&D's membership reflects the international scope of the pharmaceutical industry and includes the Canadian operations of domestic firms. As well as those with headquarters in other countries, Rx&D membership is currently made up of approximately 50 member companies.
Responsible officer name and position during the period of this registration
RUSSELL WILLIAMS,
PRESIDENT
Organization's membership or classes of membership
(a) Full Membership: Full membership is open to innovative pharmaceutical Persons which research, develop, manufacture and/or distribute pharmaceutical prescription preparations under their own labels in Canada. (b) Biopharmaceutical Membership: Biopharmaceutical membership is open to Persons who are engaged, for profit, in research and development of pharmaceutical products and/or biopharmaceutical health care products with the aim of producing, manufacturing or distributing the same under its own label. (c) Medical Research Affiliate Membership: Medical research affiliate membership is open to non-profit organizations engaged in research which have a relationship or are connected with hospitals, universities, research institutes, recognized health/disease organizations, or divisions or units thereof, whose membership, in the determination of the Board, would be consistent with the objects of the Association and would enhance the ability of the Association to attain such objects, and who are engaged in health research. (d) Associate Membership: Associate membership is open to Persons who do not qualify under any of the foregoing membership categories and whose membership, in the determination of the Board, would be consistent with the objects of the Association and would enhance the ability of the Association to attain such objects (»Associate Members«). Without limiting the generality of the foregoing, Associate Members may include contract research organizations, contract manufacturing organizations and clinical research organizations who supply goods and/or services to Full Members or Biopharmaceutical Members and other stakeholder groups.
Government funding
No government funding was received during the last completed financial year.
In-house Organization Contact Information
Address:
55 Metcalfe St.
Suite 1220
Ottawa, ON K1P 6L5
Canada
Telephone number:
613-236-0455
Ext.
425
Fax number:
613-236-6756
Lobbyists Details
Employees who lobby for the organization
- Declan Hamill,
Vice-President, Legal Affairs and Intellectual Property Policy |
Public offices held
- Normand Laberge,
Vice President, Federal Affairs and Federal, Provincial and Territorial Relations |
No public offices held
- Jacques Lefebvre,
Vice-President, Strategic Affairs & Communications |
Public offices held
- Hugh Scott,
Director, Parliamentary Affairs |
Public offices held
- Ivan Vrana,
Director, Federal, Provincial & Territorial Relations |
Public offices held
- Russell Williams,
President |
No public offices held
